<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="systematic-review" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Psychiatry</journal-id>
<journal-title>Frontiers in Psychiatry</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Psychiatry</abbrev-journal-title>
<issn pub-type="epub">1664-0640</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fpsyt.2024.1411189</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Psychiatry</subject>
<subj-group>
<subject>Systematic Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Personality disorders in individuals with functional seizures: a systematic review</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Sammarra</surname>
<given-names>Ilaria</given-names>
</name>
<xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2324783"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Martino</surname>
<given-names>Iolanda</given-names>
</name>
<xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/187065"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Marino</surname>
<given-names>Laura</given-names>
</name>
<uri xlink:href="https://loop.frontiersin.org/people/2769800"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fortunato</surname>
<given-names>Francesco</given-names>
</name>
<uri xlink:href="https://loop.frontiersin.org/people/1501643"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Gambardella</surname>
<given-names>Antonio</given-names>
</name>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/127621"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<institution>Institute of Neurology, Department of Medical and Surgical Sciences, Magna Graecia University</institution>, <addr-line>Catanzaro</addr-line>, <country>Italy</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Massimiliano Beghi, Azienda Unit&#xe0; Sanitaria Locale (AUSL) della Romagna, Italy</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Antonino Romeo, Fatebenefratelli Hospital, Italy</p>
<p>Carlo Fraticelli, Valduce Hospital, Italy</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Antonio Gambardella, <email xlink:href="mailto:a.gambardella@unicz.it">a.gambardella@unicz.it</email>
</p>
</fn>
<fn fn-type="other" id="fn003">
<p>&#x2020;These authors share first authorship</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>01</day>
<month>08</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="collection">
<year>2024</year>
</pub-date>
<volume>15</volume>
<elocation-id>1411189</elocation-id>
<history>
<date date-type="received">
<day>02</day>
<month>04</month>
<year>2024</year>
</date>
<date date-type="accepted">
<day>28</day>
<month>06</month>
<year>2024</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2024 Sammarra, Martino, Marino, Fortunato and Gambardella</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Sammarra, Martino, Marino, Fortunato and Gambardella</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>Functional seizures (FS) are classified as conversion disorders in the DSM-5 and dissociative disorders in the ICD-11, showing a multifactorial psychopathology with various psychiatric comorbidities, such as depression and anxiety. Several studies have found a correlation between FS and personality disorders, mainly those in cluster B. Within this cluster, borderline personality disorder (BPD) or borderline personality traits are the most prevalent in FS. Emotion dysregulation is a hallmark of BPD and is commonly reported in individuals with FS. Cluster C personality disorders, such as avoidant or obsessive-compulsive disorders, have also been reported in FS. In this review, we aim to evaluate the relationship between FS and personality disorders. Assessing personality disorders in the context of FS is relevant for determining the most appropriate intervention. Cognitive-behavioral therapy (CBT) is considered the first-line approach to treating FS. Among various CBT strategies, dialectical behavior therapy, which specifically targets emotion dysregulation, may be helpful for individuals with BPD. Future research should assess the advantages of systematically evaluating personality disorders in FS to address specific treatment planning and evaluate its effectiveness on seizure recurrence, psychological comorbidities, and quality of life.</p>
<sec>
<title>Systematic review registration</title>
<p>
<uri xlink:href="https://www.crd.york.ac.uk/PROSPEROFILES/509286_STRATEGY_20240203.pdf">https://www.crd.york.ac.uk/PROSPEROFILES/509286_STRATEGY_20240203.pdf</uri>, identifier CRD42024509286.</p>
</sec>
</abstract>
<kwd-group>
<kwd>functional seizures</kwd>
<kwd>personality disorders</kwd>
<kwd>cluster B personality disorder</kwd>
<kwd>borderline personality disorder</kwd>
<kwd>emotion dysregulation</kwd>
<kwd>dialectical-behavior therapy</kwd>
</kwd-group>
<counts>
<fig-count count="5"/>
<table-count count="2"/>
<equation-count count="0"/>
<ref-count count="42"/>
<page-count count="10"/>
<word-count count="4393"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-in-acceptance</meta-name>
<meta-value>Personality Disorders</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<label>1</label>
<title>Introduction</title>
<p>Psychogenic nonepileptic seizures, also known as functional seizures (FS), are defined as paroxysmal altered motor, sensory, autonomic, and/or cognitive signs and symptoms that resemble an epileptic seizure but are not caused by ictal epileptiform activity (<xref ref-type="bibr" rid="B1">1</xref>). FS are classified as a subgroup of conversion disorders (functional neurological symptom disorder) according to the DSM-5 (<xref ref-type="bibr" rid="B2">2</xref>) or as a dissociative neurological symptom disorder with non-epileptic seizures in the ICD-11 (<xref ref-type="bibr" rid="B3">3</xref>). The diagnosis reaches the highest certainty level recording a typical event at video-EEG (<xref ref-type="bibr" rid="B1">1</xref>). FS are frequently mistaken for epilepsy, delaying the correct diagnosis by an average of 7 years (<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B5">5</xref>). The misdiagnosis leads to inappropriate treatment, with a significant impact on quality of life, morbidity, and healthcare costs (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B6">6</xref>). In the general population, FS have an estimated incidence of 1.4&#x2013;4.9/100,000/year and a prevalence between 2 and 33 cases per 100,000 (<xref ref-type="bibr" rid="B7">7</xref>). Several theoretical models have been proposed to explain FS development (<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B9">9</xref>). Initially interpreted as a dissociative phenomenon, FS have been derived from a breakdown in psychological integration in response to intense stress or emotion, appearing as a sensorimotor flashback when traumatic dissociated material comes into consciousness (<xref ref-type="bibr" rid="B7">7</xref>). Accordingly, the prevalence of traumatic life events varied from 44% to 100% in FS. In particular, sexual abuse is three times more common among FS individuals, ranging from 6% to 85% (<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B10">10</xref>). In addition, childhood emotional neglect, defined as the carelessness of the affectional needs of a child, demonstrated a strong association with FS. Noteworthy, not all individuals reported past exposure to traumatizing events, configuring trauma as neither a necessary nor sufficient condition. Subsequent theory interpreted FS as avoidant/defensive reaction in response to overwhelming situations or traumatic experiences in individuals with low capacity for coping stressful life events (<xref ref-type="bibr" rid="B7">7</xref>). A variant of this model interprets FS as a physical component of emotional states not recognized or misinterpreted by individuals due to their inability to identify and/or name emotions (i.e., alexithymia) seen as unacceptable. A further model explains FS as learned behavior maintained by positive or negative reinforcement thanks to intrinsic/extrinsic benefits, like reducing anxiety, relieving duties, or getting attention (<xref ref-type="bibr" rid="B8">8</xref>). Recently, &#x201c;integrative cognitive model&#x201d; conceptualized FS as behavioral paroxysms resulting from automatic activation of learnt mental representations, defined &#x201c;seizure scaffold&#x201d; (<xref ref-type="bibr" rid="B7">7</xref>). In detail, an attack&#x2019;s semiology depends on the content of the scaffold, acquired from internal (as direct symptom experience) or external (as attendance of symptom) sources (<xref ref-type="bibr" rid="B11">11</xref>).</p>
<p>FS comprehend concomitant heterogeneous psychiatric disorders, ranging from 53 to 100% (<xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B13">13</xref>), and being able to represent predisposing/precipitating factor, underlying etiology, or consequence (<xref ref-type="bibr" rid="B14">14</xref>). Depression demonstrated a prevalence rate varying between 8.9% and 100% (<xref ref-type="bibr" rid="B13">13</xref>). Suicide risk has been shown to be greater in people with FS compared to the general population (<xref ref-type="bibr" rid="B15">15</xref>). Furthermore, the prevalence of anxiety disorders varied between 4.5% and 70%, including panic disorder and generalized anxiety disorder. FS individuals meeting the criteria for post-traumatic stress disorder (PTSD) ranged from 7% to 100% (<xref ref-type="bibr" rid="B13">13</xref>). Personality disorders (PDs) demonstrated a high prevalence among people with FS, up to 75% in some reports (<xref ref-type="bibr" rid="B13">13</xref>). Within PDs, cluster B, mainly borderline PD (BPD), appears as the most common personality phenotype (<xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B16">16</xref>). Interestingly, FS and BPD seem to have some mutually common aspects, sharing a history of traumatic experiences, depression, and PTSD (<xref ref-type="bibr" rid="B17">17</xref>). Moreover, emotional dysregulation, considered a BPD hallmark, is commonly described in FS (<xref ref-type="bibr" rid="B18">18</xref>). Likewise, cluster C PDs, such as avoidant or obsessive-compulsive, have also been reported in FS (<xref ref-type="bibr" rid="B9">9</xref>). Assessment of PDs in the context of FS could be particularly relevant in choosing therapeutic intervention.</p>
<p>As widely recognized, psychotherapy, including cognitive-behavioral therapy (CBT), is the most commonly used approach to treating FS (<xref ref-type="bibr" rid="B19">19</xref>). Dialectical-behavior therapy (DBT) is a form of CBT specifically developed for BPD targeting emotion dysregulation and has proved efficacy in FS (<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B20">20</xref>). Therefore, investigating BPD in FS individuals could be relevant to tailoring a therapeutic approach. Nevertheless, few studies evaluated the frequency of PDs in individuals with FS using DSM IV/V criteria. Moreover, systematic analysis of PD clusters found in FS is currently unavailable (<xref ref-type="bibr" rid="B13">13</xref>).</p>
<p>This systematic review aims to assess the following in the adult FS population: I) prevalence of PDs diagnosed according to DSM-IV/V or ICD-10/11; II) frequency of clusters A, B, and C in studies evaluating personality phenotypes; and III) PDs and their cluster rates compared to individuals with epilepsy across studies considering both groups.</p>
</sec>
<sec id="s2" sec-type="materials|methods">
<label>2</label>
<title>Materials and methods</title>
<sec id="s2_1">
<label>2.1</label>
<title>Search strategy and selection criteria</title>
<p>This review, following PRISMA guidelines (<xref ref-type="bibr" rid="B21">21</xref>), focuses on primary research articles published between 1950 and 2024. Studies excluded from this review include unpublished research, review articles, editorials, letters, case studies, case reports with less than five individuals, and meta-analyses. The protocol is available online on PROSPERO (<ext-link ext-link-type="uri" xlink:href="https://www.crd.york.ac.uk/PROSPEROFILES/509286_STRATEGY_20240203.pdf">https://www.crd.york.ac.uk/PROSPEROFILES/509286_STRATEGY_20240203.pdf</ext-link>) with registration number: CRD42024509286.</p>
<p>Databases PubMed, OVID Medline, and PsycINFO were searched, including the following terms:</p>
<p>(&#x201c;PNES&#x201d; OR &#x201c;psychogenic non-epileptic seizure*&#x201d; OR &#x201c;psychogenic non-epileptic seizure*&#x201d; OR &#x201c;psychogenic nonepileptic seizure*&#x201d; OR &#x201c;non-epileptic seizure*&#x201d; OR &#x201c;functional seizure*&#x201d; OR &#x201c;dissociative seizure*&#x201d; OR &#x201c;psychogenic seizure*&#x201d; OR &#x201c;pseudoseizure*&#x201d; OR &#x201c;pseudo-seizure*&#x201d;) AND (&#x201c;personality disorder*&#x201d; OR &#x201c;personality disease*&#x201d; OR &#x201c;borderline personality disorder*&#x201d; OR &#x201c;cluster-a personality disorder*&#x201d; OR &#x201c;cluster-b personality disorder*&#x201d; OR &#x201c;cluster-c personality disorder*&#x201d; OR &#x201c;narcissistic personality disorder*&#x201d; OR &#x201c;avoidant personality disorder*&#x201d; OR &#x201c;dependent personality disorder*&#x201d; OR &#x201c;obsessive-compulsive personality disorder*&#x201d; OR &#x201c;passive-aggressive personality disorder*&#x201d; OR &#x201c;schizotypal personality disorder*&#x201d; OR &#x201c;schizoid personality disorder*&#x201d; OR &#x201c;paranoid personality disorder*&#x201d; OR &#x201c;depressive personality disorder*&#x201d; OR &#x201c;antisocial personality disorder*&#x201d; OR &#x201c;histrionic personality disorder*&#x201d;).</p>
<p>The * indicates that any combination of letters after the initial string was accepted. All search words were not case-sensitive.</p>
<p>This search, performed on 03 February 2024, returned 70 articles on PubMED, 19 on OVID Medline, and 82 on PsycINFO (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref>).</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>Preferred reporting items for systematic reviews and meta-analyses (PRISMA) study flowchart.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fpsyt-15-1411189-g001.tif"/>
</fig>
<p>After the removal of duplicated articles, the combined searches produced 123 articles. No further papers were identified after searching the reference list of the included articles.</p>
</sec>
<sec id="s2_2">
<label>2.2</label>
<title>Papers&#x2019; assessment for eligibility</title>
<p>Each qualifying article underwent a thorough evaluation based on the following inclusion and exclusion criteria: availability of the full text, written in English, primary research article (case reports with &#x2265;5 individuals were included), related to humans with FS, studies enrolling individuals aged &#x2265;18 years, and PDs diagnosed according to DSM-IV/V or ICD-10/11. Restrictions on the publication&#x2019;s year were not applied. Papers regarding PDs in infants or adolescents were not considered for this review because our aims included the frequency of all PDs, and the diagnosis of antisocial PD requires at least an age of 18 years in accordance with DSM-V criteria (<xref ref-type="bibr" rid="B2">2</xref>).</p>
<p>Three independent reviewers (IM, IS, and FF) assessed each article by title and abstract/full text to determine eligibility, comparing their results. Any discrepancies were resolved through consensus among the review team (IM, IS, FF, LM, and AG).</p>
</sec>
<sec id="s2_3">
<label>2.3</label>
<title>Data extraction</title>
<p>For each article, the following data were extracted: study setting; study population and participants&#x2019; demographics and baseline characteristics; study design; year of publication; main outcome (frequency of PDs in individuals with FS); secondary outcomes (frequency of any PD phenotype in people with FS and, where available, in those with epilepsy); and information for risk of bias assessment. Three people independently extracted the data. Any disagreements were resolved by reaching a consensus within the review team.</p>
</sec>
<sec id="s2_4">
<label>2.4</label>
<title>Risk of bias</title>
<p>Two sources of bias were considered: inclusion bias and reporting bias in the included studies. To mitigate inclusion bias, each article was assessed by three independent and blinded reviewers. Any discrepancies between reviewers were resolved by reaching a consensus within the three-person review team. After the included articles were selected, the list was assessed by an additional reviewer (AG), and any problematic articles were thoroughly discussed within the team. We also rated each article according to the modified Newcastle-Ottawa Scale (NOS) for cross-sectional studies (<xref ref-type="bibr" rid="B22">22</xref>).</p>
</sec>
<sec id="s2_5">
<label>2.5</label>
<title>Statistical analysis (meta-analysis)</title>
<p>For articles that compared the prevalence of PDs and their relative clusters between FS and epileptic seizure groups, a meta-analysis was conducted using Cochrane&#x2019;s Review Manager Web tool (RevMan Web) (<ext-link ext-link-type="uri" xlink:href="https://revman.cochrane.org">https://revman.cochrane.org</ext-link>) (<xref ref-type="bibr" rid="B23">23</xref>). As the considered variables are dichotomous outcomes, the Mantel-Haenszel method was used to provide the odds ratio (OR) along with its 95% confidence interval (CI) pooled in a forest plot. Heterogeneity across the analyzed studies was evaluated through the Cochrane Q test (&#x3c7;<sup>2</sup> test) and the I-squared index (I<sup>2</sup>). A p-value of &lt;0.05 was considered statistically significant. Publication bias was assessed using funnel plots.</p>
</sec>
</sec>
<sec id="s3" sec-type="results">
<label>3</label>
<title>Results</title>
<sec id="s3_1">
<label>3.1</label>
<title>Study selection</title>
<p>As reported in <xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref>, out of the 123 articles reviewed, 13 were excluded due to full-text unavailability, 6 articles were not in English, 42 were not classified as primary research articles, 8 articles regarded individuals with age &lt;18 years, 34 had not been diagnosed with PDs according to DSM-IV/V or ICD-10/11, and 6 articles were not related to FS individuals.</p>
<p>After manual assessment, 14 (<xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref>) articles met the inclusion criteria and were retained for further analysis. The scoring of all reviewed articles is detailed in <xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Table&#xa0;1</bold>
</xref>. At the risk of bias assessed through NOS, 4/14 (<xref ref-type="bibr" rid="B24">24</xref>&#x2013;<xref ref-type="bibr" rid="B27">27</xref>) and 10/14 (<xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B28">28</xref>&#x2013;<xref ref-type="bibr" rid="B36">36</xref>) studies obtained medium-quality (4&#x2013;6 stars) and high-quality (at least 7 stars) judgments, respectively (<xref ref-type="table" rid="T2">
<bold>Table&#xa0;2</bold>
</xref>).</p>
<table-wrap id="T1" position="float">
<label>Table&#xa0;1</label>
<caption>
<p>Characteristics and results of the included studies.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" align="center">Author</th>
<th valign="middle" align="center">Year</th>
<th valign="middle" align="center">FS, n&#xb0;</th>
<th valign="middle" align="center">Age</th>
<th valign="middle" align="center">Diagnostic criteria</th>
<th valign="middle" align="center">Other groups enrolled</th>
<th valign="middle" align="center">Personality assessment</th>
<th valign="middle" align="center">PDs, n&#xb0; (%)</th>
<th valign="middle" align="center">Cluster A, n&#xb0; (%)</th>
<th valign="middle" align="center">Cluster B, n&#xb0; (%)</th>
<th valign="middle" align="center">Cluster C, n&#xb0; (%)</th>
<th valign="middle" align="center">Other PDs, n&#xb0; (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="center">Bailles et&#xa0;al. (<xref ref-type="bibr" rid="B24">24</xref>)</td>
<td valign="middle" align="center">2004</td>
<td valign="middle" align="center">30</td>
<td valign="middle" align="center">34.1 &#xb1; 12.7</td>
<td valign="middle" align="center">DSM IV</td>
<td valign="middle" align="center">None</td>
<td valign="middle" align="center">SCID II</td>
<td valign="middle" align="center">18/30 (60%)</td>
<td valign="middle" align="center">1/18 (5.6%)</td>
<td valign="middle" align="center">12/18 (66.7%)</td>
<td valign="middle" align="center">2/18 (11.1%)</td>
<td valign="middle" align="center">3/18 (16.7%)</td>
</tr>
<tr>
<td valign="middle" align="center">Binzer et&#xa0;al. (<xref ref-type="bibr" rid="B28">28</xref>)</td>
<td valign="middle" align="center">2004</td>
<td valign="middle" align="center">20</td>
<td valign="middle" align="center">27</td>
<td valign="middle" align="center">DSM IV</td>
<td valign="middle" align="center">20 with epilepsy</td>
<td valign="middle" align="center">SCID II</td>
<td valign="middle" align="center">13/20 (65%)</td>
<td valign="middle" align="center">&#x2013;</td>
<td valign="middle" align="center">7/13 (53.8%)</td>
<td valign="middle" align="center">&#x2013;</td>
<td valign="middle" align="center">&#x2013;</td>
</tr>
<tr>
<td valign="middle" align="center">D&#x2019;alessio et&#xa0;al. (<xref ref-type="bibr" rid="B29">29</xref>)</td>
<td valign="middle" align="center">2006</td>
<td valign="middle" align="center">24</td>
<td valign="middle" align="center">33.42 &#xb1; 14.08</td>
<td valign="middle" align="center">DSM IV</td>
<td valign="middle" align="center">19 with FS + epilepsy</td>
<td valign="middle" align="center">SCID II</td>
<td valign="middle" align="center">17/24 (71%)</td>
<td valign="middle" align="center">1/17 (5.9%)</td>
<td valign="middle" align="center">8/17 (47.1%)</td>
<td valign="middle" align="center">8/17 (47.1%)</td>
<td valign="middle" align="center">&#x2013;</td>
</tr>
<tr>
<td valign="middle" align="center">Direk et&#xa0;al. (<xref ref-type="bibr" rid="B30">30</xref>)</td>
<td valign="middle" align="center">2012</td>
<td valign="middle" align="center">35</td>
<td valign="middle" align="center">29.1 &#xb1; 9.2</td>
<td valign="middle" align="center">DSM IV</td>
<td valign="middle" align="center">35 with epilepsy<break/>37 healthy subjects</td>
<td valign="middle" align="center">SCID II</td>
<td valign="middle" align="center">26/35 (74%)</td>
<td valign="middle" align="center">1/26 (3.8%)</td>
<td valign="middle" align="center">21/26 (80.7%)</td>
<td valign="middle" align="center">13/26 (37.1%)</td>
<td valign="middle" align="center">&#x2013;</td>
</tr>
<tr>
<td valign="middle" align="center">Harden et&#xa0;al. (<xref ref-type="bibr" rid="B31">31</xref>)</td>
<td valign="middle" align="center">2009</td>
<td valign="middle" align="center">16</td>
<td valign="middle" align="center">45</td>
<td valign="middle" align="center">DSM IV</td>
<td valign="middle" align="center">16 with epilepsy</td>
<td valign="middle" align="center">SCID II</td>
<td valign="middle" align="center">13/16 (81%)</td>
<td valign="middle" align="center">4/13 (30.7%)</td>
<td valign="middle" align="center">11/13 (84.6%)</td>
<td valign="middle" align="center">1/13 (7.7%)</td>
<td valign="middle" align="center">&#x2013;</td>
</tr>
<tr>
<td valign="middle" align="center">Hovorka et&#xa0;al. (<xref ref-type="bibr" rid="B25">25</xref>)</td>
<td valign="middle" align="center">2007</td>
<td valign="middle" align="center">56</td>
<td valign="middle" align="center">29.6 &#xb1; 10,1</td>
<td valign="middle" align="center">ICD-10</td>
<td valign="middle" align="center">None</td>
<td valign="middle" align="center">Structured psychiatric interview</td>
<td valign="middle" align="center">25/56 (44.6%)</td>
<td valign="middle" align="center">1/25 (4%)</td>
<td valign="middle" align="center">18/25 (72%)</td>
<td valign="middle" align="center">4/25 (16%)</td>
<td valign="middle" align="center">2/25 (8%)</td>
</tr>
<tr>
<td valign="middle" align="center">Labudda et&#xa0;al. (<xref ref-type="bibr" rid="B32">32</xref>)</td>
<td valign="middle" align="center">2018</td>
<td valign="middle" align="center">67</td>
<td valign="middle" align="center">37.7 &#xb1; 12.3</td>
<td valign="middle" align="center">ICD-10</td>
<td valign="middle" align="center">42 with FS + epilepsy</td>
<td valign="middle" align="center">SCID II</td>
<td valign="middle" align="center">24/67 (35.8%)</td>
<td valign="middle" align="center">&#x2013;</td>
<td valign="middle" align="center">10/24 (41.7%)</td>
<td valign="middle" align="center">5/24 (20.8%)</td>
<td valign="middle" align="center">9/24 (37.5%)</td>
</tr>
<tr>
<td valign="middle" align="center">LaFrance et&#xa0;al. (<xref ref-type="bibr" rid="B26">26</xref>)</td>
<td valign="middle" align="center">2010</td>
<td valign="middle" align="center">38</td>
<td valign="middle" align="center">36.2 &#xb1; 13.2</td>
<td valign="middle" align="center">DSM IV</td>
<td valign="middle" align="center">None</td>
<td valign="middle" align="center">SCID II</td>
<td valign="middle" align="center">20/38 (52.6%)</td>
<td valign="middle" align="center">&#x2013;</td>
<td valign="middle" align="center">10/20 (50%)</td>
<td valign="middle" align="center">&#x2013;</td>
<td valign="middle" align="center">&#x2013;</td>
</tr>
<tr>
<td valign="middle" align="center">Nez&#x2c7;a&#xb4;dal et&#xa0;al. (<xref ref-type="bibr" rid="B27">27</xref>)</td>
<td valign="middle" align="center">2011</td>
<td valign="middle" align="center">111</td>
<td valign="middle" align="center">31.2 &#xb1; 9.7</td>
<td valign="middle" align="center">DSM IV</td>
<td valign="middle" align="center">None</td>
<td valign="middle" align="center">Psychiatric evaluation</td>
<td valign="middle" align="center">52/111 (46.8%)</td>
<td valign="middle" align="center">1/52 (1.9%)</td>
<td valign="middle" align="center">33/52 (63.5%)</td>
<td valign="middle" align="center">8/52 (15.4%)</td>
<td valign="middle" align="center">10/52 (19.2%)</td>
</tr>
<tr>
<td valign="middle" align="center">Rady et&#xa0;al. (<xref ref-type="bibr" rid="B33">33</xref>)</td>
<td valign="middle" align="center">2021</td>
<td valign="middle" align="center">33</td>
<td valign="middle" align="center">31.15 &#xb1; 7.92</td>
<td valign="middle" align="center">DSM IV</td>
<td valign="middle" align="center">33 with epilepsy</td>
<td valign="middle" align="center">SCID II</td>
<td valign="middle" align="center">29/33 (87.9%)</td>
<td valign="middle" align="center">14/29 (48.3%)</td>
<td valign="middle" align="center">23/29 (79.3%)</td>
<td valign="middle" align="center">22/29 (75.9%)</td>
<td valign="middle" align="center">&#x2013;</td>
</tr>
<tr>
<td valign="middle" align="center">Salinsky et&#xa0;al. (<xref ref-type="bibr" rid="B34">34</xref>)</td>
<td valign="middle" align="center">2019</td>
<td valign="middle" align="center">73</td>
<td valign="middle" align="center">46</td>
<td valign="middle" align="center">DSM IV</td>
<td valign="middle" align="center">64 with epilepsy</td>
<td valign="middle" align="center">SCID II</td>
<td valign="middle" align="center">30/73 (41.8%)</td>
<td valign="middle" align="center">&#x2013;</td>
<td valign="middle" align="center">&#x2013;</td>
<td valign="middle" align="center">&#x2013;</td>
<td valign="middle" align="center">&#x2013;</td>
</tr>
<tr>
<td valign="middle" align="center">Sc&#xe9;vola et&#xa0;al. (<xref ref-type="bibr" rid="B17">17</xref>)</td>
<td valign="middle" align="center">2013</td>
<td valign="middle" align="center">35</td>
<td valign="middle" align="center">37.54 &#xb1; 14.07</td>
<td valign="middle" align="center">DSM IV</td>
<td valign="middle" align="center">49 with epilepsy</td>
<td valign="middle" align="center">SCID II</td>
<td valign="middle" align="center">25/35 (71.43%)</td>
<td valign="middle" align="center">5/25 (20%)</td>
<td valign="middle" align="center">15/25 (75%)</td>
<td valign="middle" align="center">11/25 (44%)</td>
<td valign="middle" align="center">&#x2013;</td>
</tr>
<tr>
<td valign="middle" align="center">Stone et&#xa0;al. (<xref ref-type="bibr" rid="B35">35</xref>)</td>
<td valign="middle" align="center">2004</td>
<td valign="middle" align="center">20</td>
<td valign="middle" align="center">27</td>
<td valign="middle" align="center">DSM IV</td>
<td valign="middle" align="center">30 with functional disorder different form FS</td>
<td valign="middle" align="center">SCID II</td>
<td valign="middle" align="center">13/20 (65%)</td>
<td valign="middle" align="center">&#x2013;</td>
<td valign="middle" align="center">7/13 (53.8%)</td>
<td valign="middle" align="center">&#x2013;</td>
<td valign="middle" align="center">&#x2013;</td>
</tr>
<tr>
<td valign="middle" align="center">Turner et&#xa0;al. (<xref ref-type="bibr" rid="B36">36</xref>)</td>
<td valign="middle" align="center">2011</td>
<td valign="middle" align="center">22</td>
<td valign="middle" align="center">40.2 &#xb1; 14.5</td>
<td valign="middle" align="center">DSM IV</td>
<td valign="middle" align="center">21 with epilepsy<break/>10 with FS + epilepsy</td>
<td valign="middle" align="center">SCID II</td>
<td valign="middle" align="center">4/22 (18%)</td>
<td valign="middle" align="center">1/4 (25%)</td>
<td valign="middle" align="center">2/4 (50%)</td>
<td valign="middle" align="center">&#x2013;</td>
<td valign="middle" align="center">1/4 (25%)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>DSM, Diagnostic and Statistical Manual of Mental Disorder; FS, functional seizures; ICD, International Classification of Disease; PDs, personality disorders; SCID-II, Structured Clinical Interview for DSM-IV Axis II disorders.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="T2" position="float">
<label>Table&#xa0;2</label>
<caption>
<p>Quality assessment of included articles through the modified Newcastle-Ottawa Scale for cross-sectional studies.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" rowspan="2" align="center">References</th>
<th valign="top" colspan="4" align="center">Selection<xref ref-type="table-fn" rid="fnT1_1">
<sup>a</sup>
</xref>
</th>
<th valign="top" align="center">Comparability<xref ref-type="table-fn" rid="fnT1_2">
<sup>b</sup>
</xref>
</th>
<th valign="middle" colspan="2" align="center">Outcome<xref ref-type="table-fn" rid="fnT1_3">
<sup>c</sup>
</xref>
</th>
<th valign="middle" rowspan="2" align="center">Total quality score</th>
</tr>
<tr>
<th valign="top" align="center">(1)<break/>Representativeness of the sample</th>
<th valign="top" align="center">(2)<break/>Sample size</th>
<th valign="top" align="center">(3)<break/>Non-respondents</th>
<th valign="top" align="center">(4)<break/>Ascertainment of exposure</th>
<th valign="top" align="center">(1)<break/>Comparability of individuals based on the design or analysis</th>
<th valign="top" align="center">(1)<break/>Assessment of the outcome</th>
<th valign="top" align="center">(2)<break/>Statistical test</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">Bailles et&#xa0;al. (<xref ref-type="bibr" rid="B24">24</xref>)</td>
<td valign="middle" align="center">*</td>
<td valign="middle" align="center">*</td>
<td valign="middle" align="center">*</td>
<td valign="middle" align="center">*</td>
<td valign="middle" align="center"/>
<td valign="middle" align="center">**</td>
<td valign="middle" align="center"/>
<td valign="middle" align="center">6</td>
</tr>
<tr>
<td valign="top" align="left">Binzer et&#xa0;al. (<xref ref-type="bibr" rid="B28">28</xref>)</td>
<td valign="middle" align="center">*</td>
<td valign="middle" align="center">*</td>
<td valign="middle" align="center">*</td>
<td valign="middle" align="center">*</td>
<td valign="middle" align="center">**</td>
<td valign="middle" align="center">**</td>
<td valign="middle" align="center"/>
<td valign="middle" align="center">8</td>
</tr>
<tr>
<td valign="top" align="left">D&#x2019;alessio et&#xa0;al. (<xref ref-type="bibr" rid="B29">29</xref>)</td>
<td valign="middle" align="center">*</td>
<td valign="middle" align="center">*</td>
<td valign="middle" align="center">*</td>
<td valign="middle" align="center">*</td>
<td valign="middle" align="center">**</td>
<td valign="middle" align="center">**</td>
<td valign="middle" align="center"/>
<td valign="middle" align="center">8</td>
</tr>
<tr>
<td valign="top" align="left">Direk et&#xa0;al. (<xref ref-type="bibr" rid="B30">30</xref>)</td>
<td valign="middle" align="center">*</td>
<td valign="middle" align="center">*</td>
<td valign="middle" align="center">*</td>
<td valign="middle" align="center">*</td>
<td valign="middle" align="center">**</td>
<td valign="middle" align="center">**</td>
<td valign="middle" align="center"/>
<td valign="middle" align="center">8</td>
</tr>
<tr>
<td valign="top" align="left">Harden et&#xa0;al. (<xref ref-type="bibr" rid="B31">31</xref>)</td>
<td valign="middle" align="center">*</td>
<td valign="middle" align="center">*</td>
<td valign="middle" align="center">*</td>
<td valign="middle" align="center">*</td>
<td valign="middle" align="center">**</td>
<td valign="middle" align="center">**</td>
<td valign="middle" align="center"/>
<td valign="middle" align="center">8</td>
</tr>
<tr>
<td valign="top" align="left">Hovorka et&#xa0;al. (<xref ref-type="bibr" rid="B25">25</xref>)</td>
<td valign="middle" align="center">*</td>
<td valign="middle" align="center">*</td>
<td valign="middle" align="center">*</td>
<td valign="middle" align="center">*</td>
<td valign="middle" align="center"/>
<td valign="middle" align="center">**</td>
<td valign="middle" align="center"/>
<td valign="middle" align="center">6</td>
</tr>
<tr>
<td valign="top" align="left">Labudda et&#xa0;al. (<xref ref-type="bibr" rid="B32">32</xref>)</td>
<td valign="middle" align="center">*</td>
<td valign="middle" align="center">*</td>
<td valign="middle" align="center">*</td>
<td valign="middle" align="center">*</td>
<td valign="middle" align="center">**</td>
<td valign="middle" align="center">**</td>
<td valign="middle" align="center"/>
<td valign="middle" align="center">8</td>
</tr>
<tr>
<td valign="top" align="left">LaFrance et&#xa0;al. (<xref ref-type="bibr" rid="B26">26</xref>)</td>
<td valign="middle" align="center">*</td>
<td valign="middle" align="center">*</td>
<td valign="middle" align="center">*</td>
<td valign="middle" align="center">*</td>
<td valign="middle" align="center"/>
<td valign="middle" align="center">**</td>
<td valign="middle" align="center"/>
<td valign="middle" align="center">6</td>
</tr>
<tr>
<td valign="top" align="left">Nez&#x2c7;a&#xb4;dal et&#xa0;al. (<xref ref-type="bibr" rid="B27">27</xref>)</td>
<td valign="middle" align="center">*</td>
<td valign="middle" align="center">*</td>
<td valign="middle" align="center">*</td>
<td valign="middle" align="center">*</td>
<td valign="middle" align="center"/>
<td valign="middle" align="center">**</td>
<td valign="middle" align="center"/>
<td valign="middle" align="center">6</td>
</tr>
<tr>
<td valign="top" align="left">Rady et&#xa0;al. (<xref ref-type="bibr" rid="B33">33</xref>)</td>
<td valign="middle" align="center">*</td>
<td valign="middle" align="center">*</td>
<td valign="middle" align="center">*</td>
<td valign="middle" align="center">*</td>
<td valign="middle" align="center">**</td>
<td valign="middle" align="center">**</td>
<td valign="middle" align="center"/>
<td valign="middle" align="center">8</td>
</tr>
<tr>
<td valign="top" align="left">Salinsky et&#xa0;al. (<xref ref-type="bibr" rid="B34">34</xref>)</td>
<td valign="middle" align="center">*</td>
<td valign="middle" align="center">*</td>
<td valign="middle" align="center">*</td>
<td valign="middle" align="center">*</td>
<td valign="middle" align="center">**</td>
<td valign="middle" align="center">**</td>
<td valign="middle" align="center"/>
<td valign="middle" align="center">8</td>
</tr>
<tr>
<td valign="top" align="left">Sc&#xe9;vola et&#xa0;al. (<xref ref-type="bibr" rid="B17">17</xref>)</td>
<td valign="middle" align="center">*</td>
<td valign="middle" align="center">*</td>
<td valign="middle" align="center">*</td>
<td valign="middle" align="center">*</td>
<td valign="middle" align="center">**</td>
<td valign="middle" align="center">**</td>
<td valign="middle" align="center"/>
<td valign="middle" align="center">8</td>
</tr>
<tr>
<td valign="top" align="left">Stone et&#xa0;al. (<xref ref-type="bibr" rid="B35">35</xref>)</td>
<td valign="middle" align="center">*</td>
<td valign="middle" align="center">*</td>
<td valign="middle" align="center">*</td>
<td valign="middle" align="center">*</td>
<td valign="middle" align="center">**</td>
<td valign="middle" align="center">**</td>
<td valign="middle" align="center"/>
<td valign="middle" align="center">8</td>
</tr>
<tr>
<td valign="top" align="left">Turner et&#xa0;al. (<xref ref-type="bibr" rid="B36">36</xref>)</td>
<td valign="middle" align="center">*</td>
<td valign="middle" align="center">*</td>
<td valign="middle" align="center">*</td>
<td valign="middle" align="center">*</td>
<td valign="middle" align="center">**</td>
<td valign="middle" align="center">**</td>
<td valign="middle" align="center"/>
<td valign="middle" align="center">8</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="fnT1_1">
<label>a</label>
<p>A maximum of 5 stars can be awarded for the selection.</p>
</fn>
<fn id="fnT1_2">
<label>b</label>
<p>A maximum of 2 stars can be awarded for comparability.</p>
</fn>
<fn id="fnT1_3">
<label>c</label>
<p>A maximum of 3 stars can be awarded for the outcome.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="s3_2">
<label>3.2</label>
<title>Features of the included studies</title>
<p>
<xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref> summarizes the clinical characteristics of the enrolled individuals, the edition of the DSM or ICD used for PD diagnosis, the methods used for personality assessment, and the main results of all 14 studies included. In all papers included, participants have no intellectual disability, comorbidity, or other relevant conditions, such as epilepsy or drug abuse. Noteworthily, individuals with FS alone were considered for analysis. The sample size varied from 20 to 111 across studies. The age of FS participants ranged from 18 years to 65 years (mean age: 34.9). Concordantly to the literature, the female sex is preponderant across studies, reaching 65% of the study population. In 13/14 studies (<xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B24">24</xref>&#x2013;<xref ref-type="bibr" rid="B31">31</xref>, <xref ref-type="bibr" rid="B33">33</xref>&#x2013;<xref ref-type="bibr" rid="B36">36</xref>), the FS diagnosis required the recording of typical events on video-EEG, reaching the &#x201c;documented&#x201d; level in accordance with the latest diagnostic criteria (<xref ref-type="bibr" rid="B1">1</xref>). In one study (<xref ref-type="bibr" rid="B32">32</xref>), FS were determined according to the criteria of the Non-epileptic Seizures Task Force of the International League Against Epilepsy (ILAE), including individuals with diagnostic levels indicated as &#x201c;probable,&#x201d; &#x201c;clinically established,&#x201d; and &#x201c;documented&#x201d; (<xref ref-type="bibr" rid="B1">1</xref>). Groups used as FS comparisons were not homogenous among the included studies. In detail, 5/14 studies enrolled people with epilepsy (<xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B28">28</xref>, <xref ref-type="bibr" rid="B31">31</xref>, <xref ref-type="bibr" rid="B33">33</xref>, <xref ref-type="bibr" rid="B34">34</xref>), 2/14 individuals with FS plus epilepsy (<xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B32">32</xref>), and 1/14 individuals with a diagnosis of a functional disorder different from FS (<xref ref-type="bibr" rid="B35">35</xref>); in two cases, individuals with FS and individuals with epilepsy were evaluated in comparison to healthy subjects (<xref ref-type="bibr" rid="B30">30</xref>) and people with FS plus epilepsy (<xref ref-type="bibr" rid="B36">36</xref>), respectively.</p>
</sec>
<sec id="s3_3">
<label>3.3</label>
<title>Personality disorders in FS</title>
<p>The rate of PDs as comorbidity in FS ranged from 18% to 87%, with a mean of 53.7%. Diagnosis of PDs was made according to DSM-IV in 12/14 studies (<xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B24">24</xref>, <xref ref-type="bibr" rid="B26">26</xref>&#x2013;<xref ref-type="bibr" rid="B31">31</xref>, <xref ref-type="bibr" rid="B33">33</xref>&#x2013;<xref ref-type="bibr" rid="B36">36</xref>) and ICD-10 in 2/14 (<xref ref-type="bibr" rid="B25">25</xref>, <xref ref-type="bibr" rid="B32">32</xref>). In total, 12 out of 14 studies used the Structured Clinical Interview for DSM-IV Axis II Disorders (SCID II) to assess PDs (<xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B24">24</xref>, <xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B28">28</xref>&#x2013;<xref ref-type="bibr" rid="B36">36</xref>), and in 2/14 cases, diagnosis was based on psychiatric evaluation (<xref ref-type="bibr" rid="B25">25</xref>, <xref ref-type="bibr" rid="B27">27</xref>).</p>
<p>Ten out of 14 studies classified PDs in clusters (<xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B24">24</xref>, <xref ref-type="bibr" rid="B25">25</xref>, <xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B29">29</xref>&#x2013;<xref ref-type="bibr" rid="B33">33</xref>, <xref ref-type="bibr" rid="B36">36</xref>), and and in 3/14 cases only cluster B has been determined (<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B28">28</xref>, <xref ref-type="bibr" rid="B35">35</xref>). Considering the 13/14 studies that analyzed cluster B, the rate of this personality phenotype varied between 41.7% and 84.6%, with a mean of 63.4% (<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B28">28</xref>, <xref ref-type="bibr" rid="B35">35</xref>). Notably, 10 out of 14 studies assessed the prevalence of cluster A and cluster C. Cluster A subtype ranged from 0% to 48.3%, with a mean of 12.4%. Cluster C demonstrated a frequency between 7.7% and 75.9%, with a mean of 31.6% (<xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B24">24</xref>, <xref ref-type="bibr" rid="B25">25</xref>, <xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B29">29</xref>&#x2013;<xref ref-type="bibr" rid="B33">33</xref>, <xref ref-type="bibr" rid="B36">36</xref>). Four out of 14 studies described other PD phenotypes that did not meet the criteria for a specific personality cluster (<xref ref-type="bibr" rid="B24">24</xref>, <xref ref-type="bibr" rid="B25">25</xref>, <xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B32">32</xref>). In detail, two studies described 12 individuals with organic PDs (5.1%) (<xref ref-type="bibr" rid="B25">25</xref>, <xref ref-type="bibr" rid="B27">27</xref>), one reported three PDs not otherwise specified (1.3%) (<xref ref-type="bibr" rid="B24">24</xref>), the remaining counted seven personality changes after stress (3%) and two cases with combined PDs (0.9%) (<xref ref-type="bibr" rid="B32">32</xref>).</p>
<p>Moreover, 7 out of 14 studies differentiated subtypes of PDs within each cluster (<xref ref-type="bibr" rid="B24">24</xref>, <xref ref-type="bibr" rid="B25">25</xref>, <xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B30">30</xref>, <xref ref-type="bibr" rid="B32">32</xref>, <xref ref-type="bibr" rid="B33">33</xref>, <xref ref-type="bibr" rid="B36">36</xref>). Noteworthy, an individual could receive more than one PD diagnoses. Within cluster A, 11 individuals had paranoid PD (6.2%), 9 had schizoid PD (5.1%), and 7 had schizotypal PD (3.9%). Regarding cluster B, 2 individuals were diagnosed with antisocial PD (1.1%), 101 with BPD (56.7%), 19 with histrionic PD (19%), and 20 with narcissistic PD (11.2%). In relation to cluster C, 35 individuals had avoidant PD (35%), 24 dependent PD (13.5%) and 19 obsessive-compulsive PD (19%). One study reported 16 cases of passive-aggressive PD and 15 cases of depressive PDs, in accordance with the criteria reported in Appendix B of DSM-IV (<xref ref-type="bibr" rid="B33">33</xref>). These PDs are no longer listed in the DSM-V but fall under the category of other specified/unspecified personality disorder subclinical diagnoses (<xref ref-type="bibr" rid="B2">2</xref>).</p>
<p>Furthermore, 7 out of 14 studies used individuals with epilepsy as a comparison group to the FS cohort (<xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B28">28</xref>, <xref ref-type="bibr" rid="B30">30</xref>, <xref ref-type="bibr" rid="B31">31</xref>, <xref ref-type="bibr" rid="B33">33</xref>, <xref ref-type="bibr" rid="B34">34</xref>, <xref ref-type="bibr" rid="B36">36</xref>). Combining these studies suitable for meta-analysis, OR resulted greater than 1, indicating that individuals with FS have nearly three times the odds to have PDs than people with epilepsy (OR=2.81; 95% CI=1.86-4.25; I2=0%; p&lt;0.00001), as reported in <xref ref-type="fig" rid="f2"><bold>Figure 2</bold></xref>. Testing Cluster B prevalence, individuals with FS demonstrated a four-time increased OR to have this PD phenotype compared to epilepsy population (OR= 4.61; 95% CI=2.43-8.74; I2=0%; p&lt;0.00001), as displayed in <xref ref-type="fig" rid="f3"><bold>Figure 3</bold></xref>. Five out of 14 studies evaluated differences in cluster A and cluster B between FS individuals and people with epilepsy. In detail, people with FS demonstrated an OR less than 1 for cluster A PDs compared to the epilepsy population (OR=0.68; 95% CI=0.35&#x2013;1.30; I<sup>2 =</sup> 62%; p=0.024), as represented in <xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4</bold>
</xref>. Similarly, FS individuals proved an OR less than 1 to present a cluster C in comparison with people with epilepsy (OR=0.63; 95% CI=0.34&#x2013;1.16; I<sup>2 =</sup> 52%; p=0.014), as delineated in <xref ref-type="fig" rid="f5">
<bold>Figure&#xa0;5</bold>
</xref>. The funnel plot displays a symmetric distribution of included studies, indicating no publication bias (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figures&#xa0;1&#x2013;4</bold>
</xref>).</p>
<fig id="f2" position="float">
<label>Figure&#xa0;2</label>
<caption>
<p>Meta-analysis of eligible studies comparing PDs between FS individuals and the epilepsy population (ES).</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fpsyt-15-1411189-g002.tif"/>
</fig>
<fig id="f3" position="float">
<label>Figure&#xa0;3</label>
<caption>
<p>Meta-analysis of eligible studies comparing Cluster B PDs between FS individuals and the epilepsy population (ES).</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fpsyt-15-1411189-g003.tif"/>
</fig>
<fig id="f4" position="float">
<label>Figure&#xa0;4</label>
<caption>
<p>Meta-analysis of eligible studies comparing Cluster A PDs between FS individuals and the epilepsy population (ES).</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fpsyt-15-1411189-g004.tif"/>
</fig>
<fig id="f5" position="float">
<label>Figure&#xa0;5</label>
<caption>
<p>Meta-analysis of eligible studies comparing Cluster C PDs between FS individuals and the epilepsy population (ES).</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fpsyt-15-1411189-g005.tif"/>
</fig>
</sec>
</sec>
<sec id="s4" sec-type="discussion">
<label>4</label>
<title>Discussion</title>
<p>This systematic review illustrates that PDs represent a notable comorbidity in the FS population. When analyzing personality phenotypes, cluster B is the most common PD in FS, in accordance with previous literature data (<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B16">16</xref>). Although at inferior rates, cluster C and, even less, cluster A have been also attested. Among all PD phenotypes, BPD represents the most common diagnosis in FS, followed at an inferior rate by avoidant PD. In comparison to people with epilepsy, our meta-analysis demonstrated in FS individuals an increased risk of having concomitant PD, particularly those belonging to cluster B. At the same time, clusters A and C appear less likely to occur in people with FS than in those with epilepsy.</p>
<p>In the literature, the association between FS and PDs is well recognized (<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B16">16</xref>). A previous systematic review documented a PDs&#x2019; rate between 5.4% and 74.3%, while in an earlier work this comorbidity varied from 10% to 86% in FS (<xref ref-type="bibr" rid="B16">16</xref>). In our analysis, the prevalence of PDs in FS falls subtly higher, ranging from 18% to 87%. Our slightly greater rate is likely due to mandatory criteria in including exclusively studies diagnosing PD in accordance with DSM-IV/V or ICD-10/11. Nonetheless, a wide disparity in PDs prevalence in FS population has been demonstrated among studies. In a previous review, this difference was attributed to a higher rate of PDs in individuals with a longer duration of FS (<xref ref-type="bibr" rid="B16">16</xref>). We did not confirm this trend in our work. It is not known whether differences in FS clinical semiology (such as motor and non-motor manifestations) or levels of dissociation could explain this disparity. Since not all studies included in the present review assessed these features, we were unable to conduct such an analysis. Cluster B PDs, particularly BPD, have been widely demonstrated as the most prevalent personality phenotype in FS (<xref ref-type="bibr" rid="B16">16</xref>). Our analysis confirmed BPD as the most frequent PD in FS, regarding more than half of this population. Other cluster B PDs have a lower frequency. In particular, although histrionic PD shares some traits with BPD, its frequency appears lower than that expected in FS, with a prevalence not exceeding 20%. Some reports describe cluster C subtypes of personality in FS. According to our data, cluster C PDs, despite their prevalence can reach up to 75.9% in FS, proved a greater association to epilepsy. Similarly, a previous study reported cluster C more frequently in people with epilepsy than in those with FS (<xref ref-type="bibr" rid="B37">37</xref>).</p>
<p>BPD combines marked impulsivity, interpersonal relationships, self-image, and affects instability, consisting of rapidly shifts between extremely positive idealization and extremely negative devaluation about self and others (<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B20">20</xref>). The hallmark of BPD is emotional dysregulation, reflecting an inability to respond to and manage emotional transitions (<xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B38">38</xref>). Notably, people with FS frequently exhibit emotional dysregulation and instability in interpersonal relationships (<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B18">18</xref>). Additionally, individuals with BPD may commonly experience childhood sexual/emotional abuse or neglect and have higher rates of concurrent psychiatric disorders, such as depression or PTSD (<xref ref-type="bibr" rid="B20">20</xref>). Moreover, dissociative symptoms are included among the diagnostic criteria for BPD and may represent a psychological mechanism underlying FS development (<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B20">20</xref>). Likewise, the similarity between these conditions also includes anger problems, hostile coping styles and somatoform disorder in comorbidity. In this context, BPD might be interpreted as a predisposing etiological factor for FS (<xref ref-type="bibr" rid="B30">30</xref>). Interpreting psychiatric disorders in FS as mere comorbidities could be misleading (<xref ref-type="bibr" rid="B12">12</xref>). The high heterogeneity in FS clinical and psychiatric manifestations likely reflects the wide range of underlying psychopathologies (<xref ref-type="bibr" rid="B30">30</xref>). Conversely, psychiatric comorbidities might contribute to poor outcomes in FS, acting as perpetuating factors (<xref ref-type="bibr" rid="B6">6</xref>).</p>
<p>Regardless of their relationship, the identification of psychiatric disorders in FS, especially PDs, significantly impacts treatment choice. Currently, psychotherapy is the first-line therapy for both FS and BPD (<xref ref-type="bibr" rid="B19">19</xref>, <xref ref-type="bibr" rid="B20">20</xref>). CBT has been widely demonstrated to reduce attack frequency and improve quality of life in individuals with FS (<xref ref-type="bibr" rid="B19">19</xref>, <xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B39">39</xref>). To date, two CBT approaches for FS have been evaluated through randomized controlled trials. The CBT developed by Goldstein targets factors involved in the development and maintenance of attacks, interpreting FS as dissociative responses. The CBT model reported by LaFrance promotes behavior and self-control, addressing both seizures and comorbidities (<xref ref-type="bibr" rid="B19">19</xref>). Among the psychotherapies available for BPD, DBT was developed in accordance with Linehan&#x2019;s biosocial theory, which conceptualizes BPD as a pervasive dysregulation disturbance with great emotional vulnerability and a deficient ability to modulate emotions (<xref ref-type="bibr" rid="B40">40</xref>). DBT includes skill modules such as mindfulness, interpersonal effectiveness, emotion regulation, and distress tolerance (<xref ref-type="bibr" rid="B20">20</xref>, <xref ref-type="bibr" rid="B41">41</xref>). In this regard, mindfulness-based therapy has shown efficacy in FS. As mentioned above, individuals with FS could be overwhelmed by their emotions, becoming detached from them as an adaptive strategy. Mindfulness increases awareness of feelings and reinforces attention to body symptoms and their misattribution (<xref ref-type="bibr" rid="B42">42</xref>). In this light, characterizing concomitant psychiatric disorders allows for the individualization of treatment for FS. As mentioned above, individuals with FS may exhibit various psychopathologies, such as a dissociative response to a previous traumatic life event, a maladaptive response to overwhelming situations, or the automatic activation of learned mental representations. As expected, different etiopathologies and underlying defense mechanisms have been demonstrated to influence treatment. However, psychotherapy for FS tailored to concomitant psychiatric disorders has not yet been thoroughly investigated.</p>
<p>The present review has some limitations. The main limitation is the small FS sample size in each included study. Nevertheless, FS diagnosis appears quite homogeneous across studies, reaching the &#x201c;documented&#x201d; level in almost all cases (<xref ref-type="bibr" rid="B1">1</xref>). Moreover, half of the included studies evaluated the prevalence of each PD subtype, further restricting the data analysis. Additionally, the comparison groups to FS are sufficiently heterogeneous, comprising healthy subjects, people with epilepsy, and individuals with FS plus epilepsy. The epilepsy population was the most numerically represented across the included studies, allowing for a meta-analysis.</p>
<p>In conclusion, PDs have been shown to be a common comorbidity in FS. Cluster B, especially BPD, demonstrated a high prevalence in individuals with FS. Evaluating the presence of PDs, particularly BPD, may have relevance in personalizing FS treatment. Psychotherapy tailored to concomitant psychiatric disorders could be more effective in reducing the recurrence of attacks and improving quality of life. Systematic investigation of therapeutic approaches structured around psychiatric comorbidity is currently not available (<xref ref-type="bibr" rid="B39">39</xref>). Further studies are needed to clarify the potential benefits of selecting psychotherapy based on the psychiatric comorbidity of an individual, especially PDs.</p>
</sec>
<sec id="s5" sec-type="data-availability">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Material</bold>
</xref>. Further inquiries can be directed to the corresponding author.</p>
</sec>
<sec id="s6" sec-type="author-contributions">
<title>Author contributions</title>
<p>IS: Conceptualization, Data curation, Formal analysis, Writing &#x2013; original draft. IM: Conceptualization, Data curation, Writing &#x2013; review &amp; editing. LM: Conceptualization, Data curation, Writing &#x2013; review &amp; editing. FF: Conceptualization, Formal analysis, Methodology, Writing &#x2013; review &amp; editing. AG: Conceptualization, Supervision, Writing &#x2013; review &amp; editing.</p>
</sec>
</body>
<back>
<sec id="s7" sec-type="funding-information">
<title>Funding</title>
<p>The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.</p>
</sec>
<sec id="s8" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s9" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors&#xa0;and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec id="s10" sec-type="supplementary-material">
<title>Supplementary material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fpsyt.2024.1411189/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fpsyt.2024.1411189/full#supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="DataSheet_1.docx" id="SM1" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document"/>
<supplementary-material xlink:href="Table_1.xls" id="ST1" mimetype="application/vnd.ms-excel"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>LaFrance</surname> <given-names>WC</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Baker</surname> <given-names>GA</given-names>
</name>
<name>
<surname>Duncan</surname> <given-names>R</given-names>
</name>
<name>
<surname>Goldstein</surname> <given-names>LH</given-names>
</name>
<name>
<surname>Reuber</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>Minimum requirements for the diagnosis of psychogenic nonepileptic seizures: a staged approach: a report from the International League Against Epilepsy Nonepileptic Seizures Task Force</article-title>. <source>Epilepsia</source>. (<year>2013</year>) <volume>54</volume>:<page-range>2005&#x2013;18</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/epi.12356</pub-id>
</citation>
</ref>
<ref id="B2">
<label>2</label>
<citation citation-type="book">
<source>Diagnostic and statistical manual of mental disorders: DSM-5. American Psychiatric Association, American Psychiatric Association. DSM-5 Task Force</source>. <edition>5th ed</edition>. (<year>2013</year>). <publisher-loc>Arlington, VA</publisher-loc>: <publisher-name>American Psychiatric Association</publisher-name>.</citation>
</ref>
<ref id="B3">
<label>3</label>
<citation citation-type="book">
<person-group person-group-type="author">
<collab>International Classification of Diseases</collab>
</person-group>. <source>Eleventh Revision (ICD-11)</source>. <publisher-name>World Health Organization (WHO</publisher-name> (<year>2019/2021</year>).</citation>
</ref>
<ref id="B4">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baslet</surname> <given-names>G</given-names>
</name>
</person-group>. <article-title>Psychogenic non-epileptic seizures: a model of their pathogenic mechanism</article-title>. <source>Seizure</source>. (<year>2011</year>) <volume>20</volume>:<fpage>1</fpage>&#x2013;<lpage>13</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.seizure.2010.10.032</pub-id>
</citation>
</ref>
<ref id="B5">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kanemoto</surname> <given-names>K</given-names>
</name>
<name>
<surname>LaFrance</surname> <given-names>WC</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Duncan</surname> <given-names>R</given-names>
</name>
<name>
<surname>Gigineishvili</surname> <given-names>D</given-names>
</name>
<name>
<surname>Park</surname> <given-names>SP</given-names>
</name>
<name>
<surname>Tadokoro</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>PNES around the world: Where we are now and how we can close the diagnosis and treatment gaps-an ILAE PNES Task Force report</article-title>. <source>Epilepsia Open</source>. (<year>2017</year>) <volume>2</volume>:<page-range>307&#x2013;16</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/epi4.12060</pub-id>
</citation>
</ref>
<ref id="B6">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reuber</surname> <given-names>M</given-names>
</name>
<name>
<surname>Elger</surname> <given-names>CE</given-names>
</name>
</person-group>. <article-title>Psychogenic nonepileptic seizures: review and update</article-title>. <source>Epilepsy Behav</source>. (<year>2003</year>) <volume>4</volume>:<page-range>205&#x2013;16</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/S1525-5050(03)00104-5</pub-id>
</citation>
</ref>
<ref id="B7">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brown</surname> <given-names>RJ</given-names>
</name>
<name>
<surname>Reuber</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>Psychological and psychiatric aspects of psychogenic non-epileptic seizures (PNES): A systematic review</article-title>. <source>Clin Psychol Rev</source>. (<year>2016</year>) <volume>45</volume>:<page-range>157&#x2013;82</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cpr.2016.01.003</pub-id>
</citation>
</ref>
<ref id="B8">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brown</surname> <given-names>RJ</given-names>
</name>
<name>
<surname>Reuber</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>Towards an integrative theory of psychogenic non-epileptic seizures (PNES)</article-title>. <source>Clin Psychol Rev</source>. (<year>2016</year>) <volume>47</volume>:<fpage>55</fpage>&#x2013;<lpage>70</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cpr.2016.06.003</pub-id>
</citation>
</ref>
<ref id="B9">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Popkirov</surname> <given-names>S</given-names>
</name>
<name>
<surname>Asadi-Pooya</surname> <given-names>AA</given-names>
</name>
<name>
<surname>Duncan</surname> <given-names>R</given-names>
</name>
<name>
<surname>Gigineishvili</surname> <given-names>D</given-names>
</name>
<name>
<surname>Hingray</surname> <given-names>C</given-names>
</name>
<name>
<surname>Miguel Kanner</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>The aetiology of psychogenic non-epileptic seizures: risk factors and comorbidities</article-title>. <source>Epileptic Disord</source>. (<year>2019</year>) <volume>21</volume>:<page-range>529&#x2013;47</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1684/epd.2019.1107</pub-id>
</citation>
</ref>
<ref id="B10">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bodde</surname> <given-names>NM</given-names>
</name>
<name>
<surname>Brooks</surname> <given-names>JL</given-names>
</name>
<name>
<surname>Baker</surname> <given-names>GA</given-names>
</name>
<name>
<surname>Boon</surname> <given-names>PA</given-names>
</name>
<name>
<surname>Hendriksen</surname> <given-names>JG</given-names>
</name>
<name>
<surname>Mulder</surname> <given-names>OG</given-names>
</name>
<etal/>
</person-group>. <article-title>Psychogenic non-epileptic seizures&#x2013;definition, etiology, treatment and prognostic issues: a critical review</article-title>. <source>Seizure</source>. (<year>2009</year>) <volume>18</volume>:<page-range>543&#x2013;53</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.seizure.2009.06.006</pub-id>
</citation>
</ref>
<ref id="B11">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brown</surname> <given-names>RJ</given-names>
</name>
</person-group>. <article-title>Psychological mechanisms of medically unexplained symptoms: an integrative conceptual model</article-title>. <source>Psychol Bull</source>. (<year>2004</year>) <volume>130</volume>:<fpage>793</fpage>&#x2013;<lpage>812</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1037/0033-2909.130.5.793</pub-id>
</citation>
</ref>
<ref id="B12">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beghi</surname> <given-names>M</given-names>
</name>
<name>
<surname>Negrini</surname> <given-names>PB</given-names>
</name>
<name>
<surname>Perin</surname> <given-names>C</given-names>
</name>
<name>
<surname>Peroni</surname> <given-names>F</given-names>
</name>
<name>
<surname>Magaudda</surname> <given-names>A</given-names>
</name>
<name>
<surname>Cerri</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Psychogenic non-epileptic seizures: so-called psychiatric comorbidity and underlying defense mechanisms</article-title>. <source>Neuropsychiatr Dis Treat</source>. (<year>2015</year>) <volume>11</volume>:<page-range>2519&#x2013;27</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2147/NDT.S82079</pub-id>
</citation>
</ref>
<ref id="B13">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Diprose</surname> <given-names>W</given-names>
</name>
<name>
<surname>Sundram</surname> <given-names>F</given-names>
</name>
<name>
<surname>Menkes</surname> <given-names>DB</given-names>
</name>
</person-group>. <article-title>Psychiatric comorbidity in psychogenic nonepileptic seizures compared with epilepsy</article-title>. <source>Epilepsy Behav</source>. (<year>2016</year>) <volume>56</volume>:<page-range>123&#x2013;30</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.yebeh.2015.12.037</pub-id>
</citation>
</ref>
<ref id="B14">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Asadi-Pooya</surname> <given-names>AA</given-names>
</name>
<name>
<surname>Farazdaghi</surname> <given-names>M</given-names>
</name>
<name>
<surname>Asadi-Pooya</surname> <given-names>H</given-names>
</name>
<name>
<surname>Fazelian</surname> <given-names>K</given-names>
</name>
</person-group>. <article-title>Depression, anxiety, stress, and suicide risk in patients with functional seizures vs. those with epilepsy</article-title>. <source>Acta Neurol Belg</source>. (<year>2023</year>) <volume>124</volume>(<issue>1</issue>):<page-range>169&#x2013;73</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s13760-023-02365-0</pub-id>
</citation>
</ref>
<ref id="B15">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gupta</surname> <given-names>R</given-names>
</name>
<name>
<surname>Garg</surname> <given-names>D</given-names>
</name>
<name>
<surname>Kumar</surname> <given-names>N</given-names>
</name>
<name>
<surname>Singh</surname> <given-names>MB</given-names>
</name>
<name>
<surname>Shukla</surname> <given-names>G</given-names>
</name>
<name>
<surname>Goyal</surname> <given-names>V</given-names>
</name>
<etal/>
</person-group>. <article-title>Psychiatric co-morbidities and factors associated with psychogenic non-epileptic seizures: a case-control study</article-title>. <source>Seizure</source>. (<year>2020</year>) <volume>81</volume>:<page-range>325&#x2013;31</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.seizure.2020.05.007</pub-id>
</citation>
</ref>
<ref id="B16">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lacey</surname> <given-names>C</given-names>
</name>
<name>
<surname>Cook</surname> <given-names>M</given-names>
</name>
<name>
<surname>Salzberg</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>The neurologist, psychogenic nonepileptic seizures, and borderline personality disorder</article-title>. <source>Epilepsy Behav</source>. (<year>2007</year>) <volume>11</volume>:<page-range>492&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.yebeh.2007.09.010</pub-id>
</citation>
</ref>
<ref id="B17">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sc&#xe9;vola</surname> <given-names>L</given-names>
</name>
<name>
<surname>Teitelbaum</surname> <given-names>J</given-names>
</name>
<name>
<surname>Oddo</surname> <given-names>S</given-names>
</name>
<name>
<surname>Centuri&#xf3;n</surname> <given-names>E</given-names>
</name>
<name>
<surname>Loidl</surname> <given-names>CF</given-names>
</name>
<name>
<surname>Kochen</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Psychiatric disorders in patients with psychogenic nonepileptic seizures and drug-resistant epilepsy: a study of an Argentine population</article-title>. <source>Epilepsy Behav</source>. (<year>2013</year>) <volume>29</volume>:<page-range>155&#x2013;60</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.yebeh.2013.07.012</pub-id>
</citation>
</ref>
<ref id="B18">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reuber</surname> <given-names>M</given-names>
</name>
<name>
<surname>Pukrop</surname> <given-names>R</given-names>
</name>
<name>
<surname>Bauer</surname> <given-names>J</given-names>
</name>
<name>
<surname>Derfuss</surname> <given-names>R</given-names>
</name>
<name>
<surname>Elger</surname> <given-names>CE</given-names>
</name>
</person-group>. <article-title>Multidimensional assessment of personality in patients with psychogenic non-epileptic seizures</article-title>. <source>J Neurol Neurosurg Psychiatry</source>. (<year>2004</year>) <volume>75</volume>:<page-range>743&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1136/jnnp.2003.013821</pub-id>
</citation>
</ref>
<ref id="B19">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>LaFrance</surname> <given-names>WC</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Reuber</surname> <given-names>M</given-names>
</name>
<name>
<surname>Goldstein</surname> <given-names>LH</given-names>
</name>
</person-group>. <article-title>Management of psychogenic nonepileptic seizures</article-title>. <source>Epilepsia</source>. (<year>2013</year>) <volume>54 Suppl 1</volume>:<fpage>53</fpage>&#x2013;<lpage>67</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/epi.12106</pub-id>
</citation>
</ref>
<ref id="B20">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leichsenring</surname> <given-names>F</given-names>
</name>
<name>
<surname>Heim</surname> <given-names>N</given-names>
</name>
<name>
<surname>Leweke</surname> <given-names>F</given-names>
</name>
<name>
<surname>Spitzer</surname> <given-names>C</given-names>
</name>
<name>
<surname>Steinert</surname> <given-names>C</given-names>
</name>
<name>
<surname>Kernberg</surname> <given-names>OF</given-names>
</name>
</person-group>. <article-title>Borderline personality disorder: A review</article-title>. <source>JAMA</source>. (<year>2023</year>) <volume>329</volume>:<page-range>670&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1001/jama.2023.0589</pub-id>
</citation>
</ref>
<ref id="B21">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Page</surname> <given-names>MJ</given-names>
</name>
<name>
<surname>McKenzie</surname> <given-names>JE</given-names>
</name>
<name>
<surname>Bossuyt</surname> <given-names>PM</given-names>
</name>
<name>
<surname>Boutron</surname> <given-names>I</given-names>
</name>
<name>
<surname>Hoffmann</surname> <given-names>TC</given-names>
</name>
<name>
<surname>Mulrow</surname> <given-names>CD</given-names>
</name>
<etal/>
</person-group>. <article-title>The PRISMA 2020 statement: an updated guideline for reporting systematic reviews</article-title>. <source>BMJ</source>. (<year>2021</year>) <volume>372</volume>:<elocation-id>n71</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1136/bmj.n71</pub-id>
</citation>
</ref>
<ref id="B22">
<label>22</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Wells</surname> <given-names>G</given-names>
</name>
<name>
<surname>Shea</surname> <given-names>B</given-names>
</name>
<name>
<surname>O&#x2019;connell</surname> <given-names>D</given-names>
</name>
<name>
<surname>Peterson</surname> <given-names>J</given-names>
</name>
<name>
<surname>Welch</surname> <given-names>V</given-names>
</name>
<name>
<surname>Losos</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <source>The Newcastle-Ottawa Scale (Nos) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses</source>. <publisher-loc>Ottawa, ON, Canada</publisher-loc>: <publisher-name>Ottawa Hospital Research Institute</publisher-name> (<year>2000</year>).</citation>
</ref>
<ref id="B23">
<label>23</label>
<citation citation-type="book">
<person-group person-group-type="author">
<collab>Collaboration C</collab>
</person-group>. <source>Review manager (RevMan) (computer program)</source>. <publisher-loc>Copenhagen</publisher-loc>: <publisher-name>The Nordic Cochrane Centre</publisher-name> (<year>2011</year>).</citation>
</ref>
<ref id="B24">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baill&#xe9;s</surname> <given-names>E</given-names>
</name>
<name>
<surname>Pintor</surname> <given-names>L</given-names>
</name>
<name>
<surname>Fernandez-Egea</surname> <given-names>E</given-names>
</name>
<name>
<surname>Torres</surname> <given-names>X</given-names>
</name>
<name>
<surname>Matrai</surname> <given-names>S</given-names>
</name>
<name>
<surname>De Pablo</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Psychiatric disorders, trauma, and MMPI profile in a Spanish sample of nonepileptic seizure patients</article-title>. <source>Gen Hosp Psychiatry</source>. (<year>2004</year>) <volume>26</volume>:<page-range>310&#x2013;5</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.genhosppsych.2004.04.003</pub-id>
</citation>
</ref>
<ref id="B25">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hovorka</surname> <given-names>J</given-names>
</name>
<name>
<surname>Nez&#xe1;dal</surname> <given-names>T</given-names>
</name>
<name>
<surname>Herman</surname> <given-names>E</given-names>
</name>
<name>
<surname>Nemcov&#xe1;</surname> <given-names>I</given-names>
</name>
<name>
<surname>Bajacek</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>Psychogenic non-epileptic seizures, prospective clinical experience: diagnosis, clinical features, risk factors, psychiatric comorbidity, treatment outcome</article-title>. <source>Epileptic Disord</source>. (<year>2007</year>) <volume>9 Suppl 1</volume>:<page-range>S52&#x2013;58</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1684/epd.2008.0156</pub-id>
</citation>
</ref>
<ref id="B26">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>LaFrance</surname> <given-names>WC</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Keitner</surname> <given-names>GI</given-names>
</name>
<name>
<surname>Papandonatos</surname> <given-names>GD</given-names>
</name>
<name>
<surname>Blum</surname> <given-names>AS</given-names>
</name>
<name>
<surname>Machan</surname> <given-names>JT</given-names>
</name>
<name>
<surname>Ryan</surname> <given-names>CE</given-names>
</name>
<etal/>
</person-group>. <article-title>Pilot pharmacologic randomized controlled trial for psychogenic nonepileptic seizures</article-title>. <source>Neurology</source>. (<year>2010</year>) <volume>75</volume>:<page-range>1166&#x2013;73</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1212/WNL.0b013e3181f4d5a9</pub-id>
</citation>
</ref>
<ref id="B27">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ne&#x17e;&#xe1;dal</surname> <given-names>T</given-names>
</name>
<name>
<surname>Hovorka</surname> <given-names>J</given-names>
</name>
<name>
<surname>Herman</surname> <given-names>E</given-names>
</name>
<name>
<surname>N&#x11b;mcov&#xe1;</surname> <given-names>I</given-names>
</name>
<name>
<surname>Baja&#x10d;ek</surname> <given-names>M</given-names>
</name>
<name>
<surname>Stichov&#xe1;</surname> <given-names>E</given-names>
</name>
</person-group>. <article-title>Psychogenic non-epileptic seizures: our video-EEG experience</article-title>. <source>Neurol Res</source>. (<year>2011</year>) <volume>33</volume>:<fpage>694</fpage>&#x2013;<lpage>700</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1179/1743132811Y.0000000003</pub-id>
</citation>
</ref>
<ref id="B28">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Binzer</surname> <given-names>M</given-names>
</name>
<name>
<surname>Stone</surname> <given-names>J</given-names>
</name>
<name>
<surname>Sharpe</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>Recent onset pseudoseizures&#x2013;clues to aetiology</article-title>. <source>Seizure</source>. (<year>2004</year>) <volume>13</volume>:<page-range>146&#x2013;55</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/S1059-1311(03)00184-5</pub-id>
</citation>
</ref>
<ref id="B29">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>D'Alessio</surname> <given-names>L</given-names>
</name>
<name>
<surname>Giagante</surname> <given-names>B</given-names>
</name>
<name>
<surname>Oddo</surname> <given-names>S</given-names>
</name>
<name>
<surname>Silva</surname> <given-names>WW</given-names>
</name>
<name>
<surname>Sol&#xed;s</surname> <given-names>P</given-names>
</name>
<name>
<surname>Consalvo</surname> <given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Psychiatric disorders in patients with psychogenic non-epileptic seizures, with and without comorbid epilepsy</article-title>. <source>Seizure</source>. (<year>2006</year>) <volume>15</volume>:<page-range>333&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.seizure.2006.04.003</pub-id>
</citation>
</ref>
<ref id="B30">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Direk</surname> <given-names>N</given-names>
</name>
<name>
<surname>Kulaksizoglu</surname> <given-names>IB</given-names>
</name>
<name>
<surname>Alpay</surname> <given-names>K</given-names>
</name>
<name>
<surname>Gurses</surname> <given-names>C</given-names>
</name>
</person-group>. <article-title>Using personality disorders to distinguish between patients with psychogenic nonepileptic seizures and those with epileptic seizures</article-title>. <source>Epilepsy Behav</source>. (<year>2012</year>) <volume>23</volume>:<fpage>138</fpage>&#x2013;<lpage>1341</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.yebeh.2011.11.013</pub-id>
</citation>
</ref>
<ref id="B31">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harden</surname> <given-names>CL</given-names>
</name>
<name>
<surname>Jovine</surname> <given-names>L</given-names>
</name>
<name>
<surname>Burgut</surname> <given-names>FT</given-names>
</name>
<name>
<surname>Carey</surname> <given-names>BT</given-names>
</name>
<name>
<surname>Nikolov</surname> <given-names>BG</given-names>
</name>
<name>
<surname>Ferrando</surname> <given-names>SJ</given-names>
</name>
</person-group>. <article-title>A comparison of personality disorder characteristics of patients with nonepileptic psychogenic pseudoseizures with those of patients with epilepsy</article-title>. <source>Epilepsy Behav</source>. (<year>2009</year>) <volume>14</volume>:<page-range>481&#x2013;3</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.yebeh.2008.12.012</pub-id>
</citation>
</ref>
<ref id="B32">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Labudda</surname> <given-names>K</given-names>
</name>
<name>
<surname>Frauenheim</surname> <given-names>M</given-names>
</name>
<name>
<surname>Illies</surname> <given-names>D</given-names>
</name>
<name>
<surname>Miller</surname> <given-names>I</given-names>
</name>
<name>
<surname>Schrecke</surname> <given-names>M</given-names>
</name>
<name>
<surname>Vietmeier</surname> <given-names>N</given-names>
</name>
<etal/>
</person-group>. <article-title>Psychiatric disorders and trauma history in patients with pure PNES and patients with PNES and coexisting epilepsy</article-title>. <source>Epilepsy Behav</source>. (<year>2018</year>) <volume>88</volume>:<page-range>41&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.yebeh.2018.08.027</pub-id>
</citation>
</ref>
<ref id="B33">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rady</surname> <given-names>A</given-names>
</name>
<name>
<surname>Elfatatry</surname> <given-names>A</given-names>
</name>
<name>
<surname>Molokhia</surname> <given-names>T</given-names>
</name>
<name>
<surname>Radwan</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>Psychiatric comorbidities in patients with psychogenic nonepileptic seizures</article-title>. <source>Epilepsy Behav</source>. (<year>2021</year>) <volume>118</volume>:<elocation-id>107918</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.yebeh.2021.107918</pub-id>
</citation>
</ref>
<ref id="B34">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salinsky</surname> <given-names>M</given-names>
</name>
<name>
<surname>Rutecki</surname> <given-names>P</given-names>
</name>
<name>
<surname>Parko</surname> <given-names>K</given-names>
</name>
<name>
<surname>Goy</surname> <given-names>E</given-names>
</name>
<name>
<surname>Storzbach</surname> <given-names>D</given-names>
</name>
<name>
<surname>Markwardt</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Health-related quality of life in Veterans with epileptic and psychogenic nonepileptic seizures</article-title>. <source>Epilepsy Behav</source>. (<year>2019</year>) <volume>94</volume>:<page-range>72&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.yebeh.2019.02.010</pub-id>
</citation>
</ref>
<ref id="B35">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stone</surname> <given-names>J</given-names>
</name>
<name>
<surname>Sharpe</surname> <given-names>M</given-names>
</name>
<name>
<surname>Binzer</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>Motor conversion symptoms and pseudoseizures: a comparison of clinical characteristics</article-title>. <source>Psychosomatics</source>. (<year>2004</year>) <volume>45</volume>:<page-range>492&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1176/appi.psy.45.6.492</pub-id>
</citation>
</ref>
<ref id="B36">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Turner</surname> <given-names>K</given-names>
</name>
<name>
<surname>Piazzini</surname> <given-names>A</given-names>
</name>
<name>
<surname>Chiesa</surname> <given-names>V</given-names>
</name>
<name>
<surname>Barbieri</surname> <given-names>V</given-names>
</name>
<name>
<surname>Vignoli</surname> <given-names>A</given-names>
</name>
<name>
<surname>Gardella</surname> <given-names>E</given-names>
</name>
<etal/>
</person-group>. <article-title>Patients with epilepsy and patients with psychogenic non-epileptic seizures: video-EEG, clinical and neuropsychological evaluation</article-title>. <source>Seizure</source>. (<year>2011</year>) <volume>20</volume>:<page-range>706&#x2013;10</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.seizure.2011.07.001</pub-id>
</citation>
</ref>
<ref id="B37">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Galimberti</surname> <given-names>CA</given-names>
</name>
<name>
<surname>Ratti</surname> <given-names>MT</given-names>
</name>
<name>
<surname>Murelli</surname> <given-names>R</given-names>
</name>
<name>
<surname>Marchioni</surname> <given-names>E</given-names>
</name>
<name>
<surname>Manni</surname> <given-names>R</given-names>
</name>
<name>
<surname>Tartara</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>Patients with psychogenic nonepileptic seizures, alone or epilepsy-associated, share a psychological profile distinct from that of epilepsy patients</article-title>. <source>J Neurol</source>. (<year>2003</year>) <volume>250</volume>:<page-range>338&#x2013;46</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00415-003-1009-0</pub-id>
</citation>
</ref>
<ref id="B38">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carpenter</surname> <given-names>RW</given-names>
</name>
<name>
<surname>Trull</surname> <given-names>TJ</given-names>
</name>
</person-group>. <article-title>Components of emotion dysregulation in borderline personality disorder: a review</article-title>. <source>Curr Psychiatry Rep</source>. (<year>2013</year>) <volume>15</volume>:<elocation-id>335</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s11920-012-0335-2</pub-id>
</citation>
</ref>
<ref id="B39">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carlson</surname> <given-names>P</given-names>
</name>
<name>
<surname>Nicholson Perry</surname> <given-names>K</given-names>
</name>
</person-group>. <article-title>Psychological interventions for psychogenic non-epileptic seizures: A meta-analysis</article-title>. <source>Seizure</source>. (<year>2017</year>) <volume>45</volume>:<page-range>142&#x2013;50</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.seizure.2016.12.007</pub-id>
</citation>
</ref>
<ref id="B40">
<label>40</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Linehan</surname> <given-names>MM</given-names>
</name>
</person-group>. <source>Cognitive-Behavioral Treatment of Borderline Personality Disorder</source>. <publisher-loc>New York, NY</publisher-loc>: <publisher-name>Guilford Press</publisher-name> (<year>1993</year>).</citation>
</ref>
<ref id="B41">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Levy</surname> <given-names>KN</given-names>
</name>
<name>
<surname>McMain</surname> <given-names>S</given-names>
</name>
<name>
<surname>Bateman</surname> <given-names>A</given-names>
</name>
<name>
<surname>Clouthier</surname> <given-names>T</given-names>
</name>
</person-group>. <article-title>Treatment of borderline personality disorder</article-title>. <source>Psychiatr Clin North Am</source>. (<year>2018</year>) <volume>41</volume>:<page-range>711&#x2013;28</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.psc.2018.07.011</pub-id>
</citation>
</ref>
<ref id="B42">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baslet</surname> <given-names>G</given-names>
</name>
<name>
<surname>Ehlert</surname> <given-names>A</given-names>
</name>
<name>
<surname>Oser</surname> <given-names>M</given-names>
</name>
<name>
<surname>Dworetzky</surname> <given-names>BA</given-names>
</name>
</person-group>. <article-title>Mindfulness-based therapy for psychogenic nonepileptic seizures</article-title>. <source>Epilepsy Behav</source>. (<year>2020</year>) <volume>103</volume>:<elocation-id>106534</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.yebeh.2019.106534</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>